(VIANEWS) – AvalonBay Communities (AVB), Laureate Education (LAUR), Coca Cola Femsa S.A.B. de C.V. (KOF) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. AvalonBay Communities (AVB)
22.4% sales growth and 8.07% return on equity
As of September 30, 2023, the Company owned or held a direct or indirect ownership interest in 296 apartment communities containing 89,240 apartment homes in 12 states and the District of Columbia, of which 17 communities were under development and one community was under redevelopment. The Company is an equity REIT in the business of developing, redeveloping, acquiring and managing apartment communities in leading metropolitan areas in New England, the New York/New Jersey Metro area, the Mid-Atlantic, the Pacific Northwest, and Northern and Southern California, as well as in the Company's expansion regions of Raleigh-Durham and Charlotte, North Carolina, Southeast Florida, Dallas and Austin, Texas, and Denver, Colorado.
Earnings Per Share
As for profitability, AvalonBay Communities has a trailing twelve months EPS of $6.58.
PE Ratio
AvalonBay Communities has a trailing twelve months price to earnings ratio of 25.28. Meaning, the purchaser of the share is investing $25.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.07%.
Sales Growth
AvalonBay Communities’s sales growth is 4.3% for the current quarter and 22.4% for the next.
Volume
Today’s last reported volume for AvalonBay Communities is 101549 which is 84.44% below its average volume of 652848.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Sep 27, 2023, the estimated forward annual dividend rate is 6.6 and the estimated forward annual dividend yield is 4.06%.
2. Laureate Education (LAUR)
19.7% sales growth and 11.36% return on equity
Laureate Education, Inc., together with its subsidiaries, provides higher education programs and services to students through a network of universities and higher education institutions. It offers a range of undergraduate and graduate degree programs primarily in the areas of business and management, medicine and health sciences, and engineering and information technology through campus-based, online, and hybrid programs. The company provides its services in Brazil, Mexico, Chile, Peru, and the United States. The company was formerly known as Sylvan Learning Systems, Inc. and changed its name to Laureate Education, Inc. in May 2004. The company was founded in 1989 and is headquartered in Baltimore, Maryland.
Earnings Per Share
As for profitability, Laureate Education has a trailing twelve months EPS of $0.65.
PE Ratio
Laureate Education has a trailing twelve months price to earnings ratio of 20.68. Meaning, the purchaser of the share is investing $20.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.36%.
Volume
Today’s last reported volume for Laureate Education is 564861 which is 20.17% below its average volume of 707668.
Yearly Top and Bottom Value
Laureate Education’s stock is valued at $13.44 at 14:22 EST, under its 52-week high of $14.81 and way above its 52-week low of $9.24.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Laureate Education’s EBITDA is 1.77.
Sales Growth
Laureate Education’s sales growth is 19.6% for the present quarter and 19.7% for the next.
3. Coca Cola Femsa S.A.B. de C.V. (KOF)
18.5% sales growth and 17.07% return on equity
Coca-Cola FEMSA, S.A.B. de C.V., a franchise bottler, produces, markets, sells, and distributes Coca-Cola trademark beverages. The company offers sparkling beverages, including colas and flavored sparkling beverages; and waters and still beverages, such as juice drinks, coffee, teas, milk, value-added dairy products, sports drinks, energy drinks, and plant-based drinks. It provides a portfolio of products through retail outlets, such as wholesale supermarkets, discount stores, and convenience stores; retailers, such as restaurants and bars, as well as stadiums, auditoriums, and theaters; points-of-sale outlets; and home delivery and other locations. The company also distributes and sells Heineken beer products in its Brazilian territories. It operates in Mexico, Guatemala, Nicaragua, Costa Rica, Panama, Colombia, Brazil, Argentina, and Uruguay. Coca-Cola FEMSA, S.A.B. de C.V. was founded in 1979 and is based in Mexico City, Mexico. Coca-Cola FEMSA, S.A.B. de C.V. is a subsidiary of Fomento Economico Mexicano, S.A.B. de C.V.
Earnings Per Share
As for profitability, Coca Cola Femsa S.A.B. de C.V. has a trailing twelve months EPS of $0.7.
PE Ratio
Coca Cola Femsa S.A.B. de C.V. has a trailing twelve months price to earnings ratio of 107.71. Meaning, the purchaser of the share is investing $107.71 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.07%.
Volume
Today’s last reported volume for Coca Cola Femsa S.A.B. de C.V. is 129569 which is 15.51% below its average volume of 153356.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.1%, now sitting on 242.07B for the twelve trailing months.
4. United Therapeutics Corporation (UTHR)
16.2% sales growth and 17.52% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $18.13.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 12.38. Meaning, the purchaser of the share is investing $12.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.52%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 3.5% and 64%, respectively.
Moving Average
United Therapeutics Corporation’s value is under its 50-day moving average of $226.01 and under its 200-day moving average of $230.08.
Volume
Today’s last reported volume for United Therapeutics Corporation is 352227 which is 18.88% above its average volume of 296276.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend yield is 6.35%.
5. Hercules Technology Growth Capital (HTGC)
14.2% sales growth and 20.94% return on equity
Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, energy technology, sustainable and renewable technology, and life sciences. Within technology the firm focuses on advanced specialty materials and chemicals; communication and networking, consumer and business products; consumer products and services, digital media and consumer internet; electronics and computer hardware; enterprise software and services; gaming; healthcare services; information services; business services; media, content and information; mobile; resource management; security software; semiconductors; semiconductors and hardware; and software sector. Within energy technology, it invests in agriculture; clean technology; energy and renewable technology, fuels and power technology; geothermal; smart grid and energy efficiency and monitoring technologies; solar; and wind. Within life sciences, the firm invests in biopharmaceuticals; biotechnology tools; diagnostics; drug discovery, development and delivery; medical devices and equipment; surgical devices; therapeutics; pharma services; and specialty pharmaceuticals. It also invests in educational services. The firm invests primarily in United States based companies and considers investment in the West Coast, Mid-Atlantic regions, Southeast and Midwest; particularly in the areas of software, biotech and information services. The firm prefers to invest between $10 million to $250 million in equity per transactions. It invests generally between $1 million to $40 million in companies focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm invests primarily in private companies but also have investments in public companies. For equity investments, the firm seeks to represent a controlling interest in its portfolio companies which may exceed 25% of the voting securities of such companies. The firm seeks to invest a limited portion of its assets in equipment-based loans to early-stage prospective portfolio companies. These loans are generally for amounts up to $3 million but may be up to $15 million for certain energy technology venture investments. The firm allows certain debt investments have the right to convert a portion of the debt investment into equity. It also co-invests with other private equity firms. The firm seeks to exit its investments through initial public offering, a private sale of equity interest to a third party, a merger or an acquisition of the company or a purchase of the equity position by the company or one of its stockholders. The firm has structured debt with warrants which typically have maturities of between two and seven years with an average of three years; senior debt with an investment horizon of less than three years; equipment loans with an investment horizon ranging from three to four years; and equity related securities with an investment horizon ranging from three to seven years. The firm prefers to invest through its balance sheet capital. The firm formerly known as Hercules Technology Growth Capital, Inc. Hercules Capital, Inc. was founded in December 2003 and is based in Palo Alto, California with additional offices in Connecticut; Boston, Massachusetts; San Diego, California; Westport, Connecticut; Elmhurst, Illinois; Santa Monica, California; McLean, Virginia; New York, New York; Radnor, Pennsylvania; and Washington, District of Columbia and London, United Kingdom.
Earnings Per Share
As for profitability, Hercules Technology Growth Capital has a trailing twelve months EPS of $2.25.
PE Ratio
Hercules Technology Growth Capital has a trailing twelve months price to earnings ratio of 6.71. Meaning, the purchaser of the share is investing $6.71 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.94%.
Volume
Today’s last reported volume for Hercules Technology Growth Capital is 785639 which is 19.54% below its average volume of 976512.
6. Global Payments (GPN)
8.7% sales growth and 3.97% return on equity
Global Payments Inc. provides payment technology and software solutions for card, check, and digital-based payments in the Americas, Europe, and the Asia-Pacific. It operates through three segments: Merchant Solutions, Issuer Solutions, and Consumer Solutions. The Merchant Solutions segment offers authorization, settlement and funding, customer support, chargeback resolution, terminal rental, sales and deployment, payment security, and consolidated billing and reporting services. This segment also provides an array of enterprise software solutions that streamline business operations of its customers in various vertical markets; and value-added solutions and services, such as point-of-sale software, analytics and customer engagement, human capital management, and payroll. The Issuer Solutions segment offers solutions that enable financial institutions and retailers to manage their card portfolios through a platform; and commercial payments, and account payables and electronic payment alternatives solutions for businesses and governments. The Consumer Solutions segment provides general purpose reloadable prepaid debit and payroll cards, demand deposit accounts, and other financial service solutions to the underbanked and other consumers, and businesses under the Netspend and other brands. It markets its products and services through direct sales force, trade associations, agent and enterprise software providers, referral arrangements with value-added resellers, and independent sales organizations. The company was founded in 1967 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, Global Payments has a trailing twelve months EPS of $3.28.
PE Ratio
Global Payments has a trailing twelve months price to earnings ratio of 33.21. Meaning, the purchaser of the share is investing $33.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.97%.
Volume
Today’s last reported volume for Global Payments is 265008 which is 84.19% below its average volume of 1676620.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Global Payments’s EBITDA is 4.63.
Yearly Top and Bottom Value
Global Payments’s stock is valued at $108.94 at 14:22 EST, way below its 52-week high of $129.70 and way above its 52-week low of $92.27.
7. Allegion plc Ordinary Shares (ALLE)
5.1% sales growth and 55.05% return on equity
Allegion plc manufactures and sells mechanical and electronic security products and solutions worldwide. The company offers door closers and controls; doors and door systems; electronic security products; electronic, biometric and mobile access control systems; exit devices; locks, locksets, portable locks, and key systems; time, attendance, and workforce productivity systems; and other accessories. The company sells its products and solutions to end-users in commercial, institutional, and residential facilities, including education, healthcare, government, hospitality, commercial office, and single and multi-family residential markets under the CISA, Interflex, LCN, Schlage, SimonsVoss, and Von Duprin brands. It sells its products and solutions through distribution and retail channels, such as specialty distribution, e-commerce, and wholesalers, as well as through various retail channels comprising do-it-yourself home improvement centers, on-line and e-commerce platforms, and small specialty showroom outlets. Allegion plc was incorporated in 2013 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, Allegion plc Ordinary Shares has a trailing twelve months EPS of $6.32.
PE Ratio
Allegion plc Ordinary Shares has a trailing twelve months price to earnings ratio of 16.38. Meaning, the purchaser of the share is investing $16.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 55.05%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.5%, now sitting on 3.61B for the twelve trailing months.
Yearly Top and Bottom Value
Allegion plc Ordinary Shares’s stock is valued at $103.49 at 14:22 EST, way under its 52-week high of $128.36 and above its 52-week low of $95.94.
Sales Growth
Allegion plc Ordinary Shares’s sales growth is 4.7% for the present quarter and 5.1% for the next.
